Jay M. Moyes - Jun 13, 2025 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Role
Director
Signature
/s/ Gordon Esplin as attorney-in-fact for Jay M. Moyes
Stock symbol
PBYI
Transactions as of
Jun 13, 2025
Transactions value $
-$74,800
Form type
4
Date filed
6/17/2025, 07:46 PM
Previous filing
Jun 13, 2025
Next filing
Aug 27, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MOYES JAY M Director C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES /s/ Gordon Esplin as attorney-in-fact for Jay M. Moyes 2025-06-17 0001191062

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PBYI Common Stock Sale -$74.8K -22K -29.21% $3.40 53.3K Jun 13, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Adoption date of referenced 10b5-1(c) plan is: 03/12/2025
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.34 to $3.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.